hcp.loloestrin.comLo Loestrin® Fe – For Healthcare Providers

FOR U.S. HEALTHCARE PROFESSIONALS ONLY Important Safety Information Prescribing Information Patient Site Home Why Lo Loestrin Fe? Is Lo Loestrin Fe Right for Her? HCP Resources Support for Your Practice Savings Program Formulary Coverage Request a Rep Request Samples Patient Site SAMPLES 3 Reasons to Give Us a Call Speak to an AbbVie representative today to: Learn more about Lo Loestrin Fe Request product samples Order patient support materials Call 1.844.950.LOLO (5656) US-LOL-220142 Lo Loestrin Fe Start her on Lo Loestrin ® Fe A unique 24/2/2 regimen with a short, 2-day hormone-free interval Why Lo Loestrin Fe › For Pregnancy Prevention * There is only ONE Lo Loestrin ® Fe The oral contraceptive (OC) with the lowest daily dose of estrogen (10 mcg) Is Lo Loestrin Fe Right for Her? › * The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) 35 kg/m 2 has not been evaluated. Lo Loestrin ® Fe is the #1-prescribed branded oral contraceptive 1 Get HCP Resources › SAMPLES SAMPLES Request Samples Savings Program Formulary Coverage Lowest Daily Estrogen Dose The only available ultra-low-dose oral contraceptive (OC) with just 10 mcg of ethinyl estradiol—the lowest daily dose of estrogen among all available OCs 3,4 Unique 24/2/2 Regimen With a short, 2-day hormone-free interval 3 Pregnancy Prevention that may also provide short, lighter periods 3,5 Mean duration of withdrawal bleeding was 2 days per cycle Patient-reported intensity of withdrawal bleeding was lighter than normal Lo Loestrin ® Fe provides brand consistency at the pharmacy There is no generic equivalent available. 4 A survey † of more than 1000 current and potential OC users found that 5 : are interested ‡ in an OC with the lowest amount of daily estrogen worry § about the amount of hormones they are exposed to through the use of OCs † Source: Online survey conducted by Harris Poll on behalf of Allergan USA, Inc., between July 7-14, 2014, among 1005 U.S. women aged 18-45 currently using OCs or considering use in the next 6 months. ‡ Survey respondents could choose from the following to indicate their interest in an OC with the lowest amount of daily estrogen: extremely interested, very interested, somewhat interested, and not at all interested. The 93% value represents those who answered extremely interested, very interested, and somewhat interested. § Survey respondents could choose from the following to indicate their level of worry about the amount of hormones they are exposed to through the use of OCs: extremely worried, very worried, somewhat worried, and not at all worried. The 78% value represents those who answered extremely worried, very worried, and somewhat worried. Lo Loestrin Fe is widely covered and available at $0 out-of-pocket cost for many patients 5,6 ~80% of commercially insured patients can access Lo Loestrin Fe 6 ~58% of Lo Loestrin Fe prescriptions were filled at $0 out-of-pocket cost 5 Check Formulary Coverage › Data are not guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety. INDICATION Lo Loestrin® Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by women to prevent pregnancy. The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of 35 kg/m 2 has not been evaluated. IMPORTANT SAFETY INFORMATION WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. Contraindications Lo Loestrin Fe is contraindicated in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. Warnings and Precautions Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued. Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are prediabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternative contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. Lo Loestrin Fe should be discontinued during pregnancy. Adverse Reactions In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression. Patients should be counseled that COCs do not protect against HIV infection (AIDS) and other sexually transmitted diseases. US-LOL-230029 Please see full Prescribing Information, including Boxed Warning , for Lo Loestrin Fe. IMPORTANT SAFETY INFORMATION INDICATION Lo Loestrin® Fe is an estrogen/progestin combination oral contraceptive (COC) indicated for use by women to prevent pregnancy. The efficacy of Lo Loestrin Fe in women with a body mass index (BMI) of 35 kg/m 2 has not been evaluated. IMPORTANT SAFETY INFORMATION WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke. Contraindications Lo Loestrin Fe is contraindicated in women with a high risk of arterial or venous thrombotic diseases, liver tumors (benign or malignant) or liver disease, undiagnosed abnormal uterine bleeding, or breast cancer, now or in the past, and in women using Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. Warnings and Precautions Discontinue Lo Loestrin Fe if a thrombotic event occurs, and at least 4 weeks before and through 2 weeks after major surgery. Lo Loestrin Fe should not be started any earlier than 4 weeks after delivery in women who are not breastfeeding. If jaundice occurs, treatment should be discontinued. Lo Loestrin Fe should not be prescribed for women with uncontrolled hypertension or hypertension with vascular disease. Women who are prediabetic or diabetic should be monitored while using Lo Loestrin Fe. Alternative contraceptive methods should be considered for women with uncontrolled dyslipidemia. Patients using Lo Loestrin Fe who have a significant change in headaches or irregular bleeding or amenorrhea should be evaluated. Lo Loestrin Fe should be discontinued during pregnancy. Adverse Reactions In the clinical trial for Lo Loestrin Fe, serious adverse reactions included deep vein thrombosis, ovarian vein thrombosis, and cholecystitis. The most common adverse reactions (incidence ≥2%) were nausea/vomiting, headache, bleeding irregularities, dysmenorrhea, weight fluctuation, breast tenderness, acne, abdominal pain, anxiety, and depression....